Quinagolide is a dopamine D2 receptor agonist used for the treatment of hyperprolactinemia. Hyperprolalctinaemia is associated with gonadal dysfunction, including infertility and reduced libido, as well as long-term complications such as osteoporosis.
- Mechanism
- Curator reviewed · 2 references
Prolactin secretion from the lactotroph cells present in the anterior pituiatry gland is under tonic inhibitory control mediated by dopaminergic signalling via D2 receptors. Quinagolide selectively binds to D2 receptors expressed on the surface of lactotroph cells with high affinity which results in reduced adenylyl cyclase activity, reduced intracellular cyclic adenosine monophosphate and inhibited prolactin secretion. It also binds to D1 receptors but with low affinity and little clinical relevance.
- Primary indication
- Indicated for the treatment of hyperprolactinemia (idiopathic or originating from a prolactin-secreting pituitary microadenoma or macroadenoma).Curator reviewed · 4 structured indications
- Formula / weight
- C20H33N3O3S · 395.56 g/mol (avg)
- First approval
- Canada, 2004
Resolves to
GDFGTRDCCWFXTG-ZIFCJYIRSA-NSMILES[H][C@]12C[C@@H](CN(CCC)[C@]1([H])CC1=CC=CC(O)=C1C2)NS(=O)(=O)N(CC)CCWhat you can answer from here — as of September 29, 2026
Which drugs share a target with Quinagolide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account